What are the risk factors for various multidrug-resistant organisms (MDROs) such as methicillin‑resistant Staphylococcus aureus (MRSA), vancomycin‑resistant Enterococcus (VRE), ESBL‑producing Enterobacteriaceae, carbapenem‑resistant Enterobacteriaceae (CRE), multidrug‑resistant Pseudomonas aeruginosa, and multidrug‑resistant Acinetobacter baumannii?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Risk Factors for Multidrug-Resistant Organisms (MDROs)

The most critical risk factors for MDRO acquisition include ICU admission, prior broad-spectrum antibiotic exposure (particularly carbapenems, aminoglycosides, and cotrimoxazole), use of invasive medical devices, prolonged hospitalization, and being bedridden, with specific risk profiles varying by pathogen type. 1, 2

General Risk Factors Across All MDROs

Healthcare-Associated Factors

  • ICU admission represents the single strongest predictor, with 8.7-fold increased odds of MDRO infection compared to surgical units 1
  • Prolonged hospitalization (>72 hours ICU stay specifically increases risk) 3
  • Invasive procedures and high invasive device scores 2
  • Prior colonization or infection with MDROs 4

Antibiotic Exposure Patterns

The specific antibiotics matter significantly:

  • High-risk antibiotics: Cotrimoxazole, amikacin, and imipenem show 4.3-fold increased odds of MDRO infections 1
  • Broad-spectrum cephalosporins and aminoglycosides are independent risk factors 2
  • Protective factor: Cefazolin use is associated with 92% lower risk (OR=0.080) 1
  • Recent antimicrobial exposure within 6 months 3, 4

Patient-Specific Factors

  • Age >60 years accounts for 53.2% of MDRO cases 5
  • Male sex 6
  • Being bedridden or having limited functional status 2
  • Chronic wounds 6
  • Use of acid-suppressive medications (5.3-fold increased odds) 1

Comorbidities

  • Diabetes mellitus 1
  • Hypertension 1
  • Notable exception: Malignant disease shows protective effect (OR=0.2) in some studies, likely due to different antibiotic exposure patterns 2

Pathogen-Specific Risk Factors

MRSA (Methicillin-Resistant Staphylococcus aureus)

  • Highest prevalence in Asia (25.6%) and long-term care facilities 6
  • Community-associated MRSA now endemic in several geographical areas 4
  • Outbreaks occur in frail populations and at-risk clusters 4

VRE (Vancomycin-Resistant Enterococcus)

  • Highest prevalence in North America (4.0%) 6
  • Healthcare facility exposure regardless of timing 3
  • Central venous line use 3

ESBL-Producing Enterobacterales

  • Highest global prevalence in Asia (71.6%) 6
  • Increasing trend observed starting in 2015 6
  • Most commonly isolated from stool/rectal swabs (78.3% E. coli) 3

CRE (Carbapenem-Resistant Enterobacterales)

  • Highest prevalence in Asia (6.9%) 6
  • Accounts for 65.3% of all MDROs in recent South Indian data 5
  • Klebsiella pneumoniae predominates among CRE isolates 5
  • Severe comorbidities and prolonged hospitalization are key 4

Multidrug-Resistant Pseudomonas aeruginosa

  • Highest prevalence in North America (5.4%) 6
  • ICU stay is dominant risk factor 2
  • Chronic wounds, especially in community-acquired SSTI 4
  • Recent antimicrobial exposure 4
  • Increasing trend since 2015 6

Carbapenem-Resistant Acinetobacter baumannii (CRAB)

  • Highest prevalence in North America (15.0%) 6
  • Second most common MDRO (11.3%) in recent tertiary care data 5
  • Endemic in healthcare settings 4
  • Limited meropenem susceptibility (only 16.3%) 5

Geographic and Temporal Variations

Asia shows highest overall MDRO burden, particularly for ESBL-producing organisms and CRE 6. North America leads in VRE, MDR Pseudomonas, and MDR Acinetobacter prevalence 6.

Recent trends (2015-2020) show:

  • Increasing: MDR P. aeruginosa, ESBL Enterobacterales 6
  • Decreasing: CRE, MDR A. baumannii, VRE, MRSA, C. difficile 6

Clinical Outcomes and Mortality

MDRO infections carry 4.4-fold increased mortality risk compared to susceptible organisms 2. Additional adverse outcomes include:

  • Prolonged hospital stay (2-fold hazard ratio) 2
  • Increased requirement for invasive procedures (5.4-fold) 2
  • Poorer functional status at discharge 2
  • Higher discharge rates to rehabilitation or chronic care facilities 2
  • Overall mortality of 25.5% in MDRO infections, with 94% clinically attributed to infection 5

Critical Pitfalls to Avoid

  1. Do not assume community-acquired infections are MDRO-free: Community-associated MRSA is now endemic, and P. aeruginosa can cause community-acquired SSTI in patients with chronic wounds 4

  2. Prior antibiotic exposure matters more than comorbidities: The type of antibiotic used is more predictive than the number of comorbid conditions 2

  3. ICU patients require different risk stratification: The epidemiology is complex with clonal spread; two PFGE clones can dominate an ICU 2

  4. Pediatric populations show surprisingly high carriage rates: 68.3% MDRO carriage at admission in one study, with ESBL E. coli predominating 3

Practical Risk Stratification Algorithm

High-risk patients requiring empiric MDRO coverage:

  • ICU admission + any invasive device + recent broad-spectrum antibiotics
  • Prior MDRO colonization/infection
  • Hospitalization >72 hours with invasive procedures
  • Age >60 + chronic wounds + recent antibiotic use
  • Acid-suppressive medication + healthcare facility exposure

Moderate-risk patients:

  • Non-ICU hospitalization + single risk factor (diabetes, recent antibiotics, or invasive device)
  • Long-term care facility residents

Lower-risk patients:

  • Community-acquired infection without healthcare exposure
  • No recent antibiotic use
  • No chronic wounds or invasive devices

The guideline emphasizes that infectious disease specialist consultation is recommended for all MDRO infections given the complexity of treatment optimization and limited active antimicrobial agents 7.

References

1
Research

Assessment of risk factors associated with multidrug-resistant organism infections among patients admitted in a tertiary hospital - a retrospective study.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2023

Related Questions

What empiric antibiotics should be given to a patient needing broad‑spectrum intravenous coverage for Gram‑negative rods, anaerobes, and possible Pseudomonas, considering β‑lactam allergy and MRSA risk?
What are the differences between multidrug‑resistant (MDR), pan‑resistant, and carbapenem‑resistant Enterobacterales (CRE) organisms?
What antibiotic regimen is appropriate for a patient with an infected amputation site who is allergic to meropenem and vancomycin?
What antibiotics should be used to treat carbapenem‑resistant Pseudomonas aeruginosa isolated from broncho‑alveolar lavage in an adult patient with normal renal function?
What is the first‑line antibiotic regimen for a patient with systemic signs of infection (fever, tachycardia, leukocytosis) or who is immunocompromised, and what alternative should be used if the patient has a penicillin allergy?
Can an 81-year-old man’s hemoglobin decrease from 14 g/dL to 9.6 g/dL over six months as a result of progressively declining renal function?
What is the appropriate treatment for a Staphylococcus epidermidis infection between the fingers?
Can a patient who has undergone coil embolization of a cerebral artery safely undergo MRI?
What is the appropriate dosing regimen for eperisone in adults, including adjustments for elderly patients, children under 12 years, and those with mild to moderate renal or hepatic impairment?
In a patient with bleeding hemorrhoids, is Anusol HC (hydrocortisone and phenylephrine) appropriate to use?
What is the most likely diagnosis for a 29-year-old male with microcytic, hypochromic anemia and target cells?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.